News | ERC

Error message

Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in _konnu_footer() (line 149 of /home/erc/web/erc-immunotherapy.com/public_html/sites/all/modules/konnu/konnu.module).

News Publications

2025 ERC Financial Statements

2024 ERC Financial Statements

2023 ERC Financial Statements

CEO Statement 2023/2024

ERC Belgium balance sheet for the financial year ending 31 Dec 2022

CEO STATEMENT 2022/2023

ERC Granted FDA Fast Track Designation for Sitoiganap in Patients with Recurrent Glioblastoma

ERC Announces Publication of Positive Efficacy Data with Sitoiganap in Patients with Recurrent Glioblastoma

ERC Belgium S.A. (ERC), announced publication of its most recent efficacy data in the May 2022 edition of Frontiers in Oncology.

ERC Belgium balance sheet for the financial year ending 31 Dec 2021

Download the ERC Belgium balace sheet for the financial year ending 31 Dec 2021.

CEO STATEMENT 2021/2022

ERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671/SITOIGANAP (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma

ERC receives a positive Opinion to commence a paediatric investigation plan(clinical trial) from the European Medicines Agency.

12 Month Progress Report 30/04/2019-30/04/2020

LATEST SITUATION – CEO STATEMENT

In Q2 2020 after enrolling about 40 patients in the Phase II clinical trial, ERC will submit its request for commercialization in the USA

Pages